Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study

Julie E. Chang, Thomas Havighurst, Kyungmann Kim, Jens Eickhoff, Anne M. Traynor, Rachel Kirby-Slimp, Lynn M. Volk, Jae Werndli, Ronald S. Go, Matthias Weiss, Jules Blank, Brad S. Kahl

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Bendamustine + rituximab (BR) has demonstrated high response rates in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). However, progression-free survival (PFS) after BR is

Original languageEnglish (US)
JournalBritish Journal of Haematology
DOIs
StateAccepted/In press - 2016
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Maintenance
Disease-Free Survival
lenalidomide
Rituximab
Bendamustine Hydrochloride

Keywords

  • Bendamustine
  • Chronic lymphocytic leukaemia
  • Lenalidomide
  • Maintenance
  • Rituximab
  • Small lymphocytic lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma : A Wisconsin Oncology Network Study. / Chang, Julie E.; Havighurst, Thomas; Kim, Kyungmann; Eickhoff, Jens; Traynor, Anne M.; Kirby-Slimp, Rachel; Volk, Lynn M.; Werndli, Jae; Go, Ronald S.; Weiss, Matthias; Blank, Jules; Kahl, Brad S.

In: British Journal of Haematology, 2016.

Research output: Contribution to journalArticle

Chang, Julie E. ; Havighurst, Thomas ; Kim, Kyungmann ; Eickhoff, Jens ; Traynor, Anne M. ; Kirby-Slimp, Rachel ; Volk, Lynn M. ; Werndli, Jae ; Go, Ronald S. ; Weiss, Matthias ; Blank, Jules ; Kahl, Brad S. / Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma : A Wisconsin Oncology Network Study. In: British Journal of Haematology. 2016.
@article{d221a31ecd75447fa5f2ae48e84652e1,
title = "Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study",
abstract = "Bendamustine + rituximab (BR) has demonstrated high response rates in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). However, progression-free survival (PFS) after BR is",
keywords = "Bendamustine, Chronic lymphocytic leukaemia, Lenalidomide, Maintenance, Rituximab, Small lymphocytic lymphoma",
author = "Chang, {Julie E.} and Thomas Havighurst and Kyungmann Kim and Jens Eickhoff and Traynor, {Anne M.} and Rachel Kirby-Slimp and Volk, {Lynn M.} and Jae Werndli and Go, {Ronald S.} and Matthias Weiss and Jules Blank and Kahl, {Brad S.}",
year = "2016",
doi = "10.1111/bjh.13957",
language = "English (US)",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma

T2 - A Wisconsin Oncology Network Study

AU - Chang, Julie E.

AU - Havighurst, Thomas

AU - Kim, Kyungmann

AU - Eickhoff, Jens

AU - Traynor, Anne M.

AU - Kirby-Slimp, Rachel

AU - Volk, Lynn M.

AU - Werndli, Jae

AU - Go, Ronald S.

AU - Weiss, Matthias

AU - Blank, Jules

AU - Kahl, Brad S.

PY - 2016

Y1 - 2016

N2 - Bendamustine + rituximab (BR) has demonstrated high response rates in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). However, progression-free survival (PFS) after BR is

AB - Bendamustine + rituximab (BR) has demonstrated high response rates in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). However, progression-free survival (PFS) after BR is

KW - Bendamustine

KW - Chronic lymphocytic leukaemia

KW - Lenalidomide

KW - Maintenance

KW - Rituximab

KW - Small lymphocytic lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84959449989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959449989&partnerID=8YFLogxK

U2 - 10.1111/bjh.13957

DO - 10.1111/bjh.13957

M3 - Article

C2 - 26913697

AN - SCOPUS:84959449989

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

ER -